{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(3)"],"submitter":["Mao-Draayer Y"],"funding":["Novartis Pharmaceuticals Corporation"],"pubmed_abstract":["<h4>Background</h4>Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood.<h4>Objective</h4>Investigate fingolimod's temporal effects on immune cell subsets, and safety outcomes.<h4>Methods</h4>In FLUENT, a 12-month, prospective, non-randomized, open-label, phase IV study, adult participants received fingolimod 0.5 mg/day. Changes in immune cell subsets, anti-John Cunningham virus (JCV) antibody index, and serum neurofilament levels were assessed.<h4>Results</h4>165 fingolimod-naive and 217 participants treated for 2-12 years in routine clinical practice were enrolled. Levels of all monitored peripheral lymphocyte subsets were reduced from month 3 in fingolimod-naive participants. Greates"],"journal":["Multiple sclerosis journal - experimental, translational and clinical"],"pagination":["20552173221115023"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9346260"],"repository":["biostudies-literature"],"pubmed_title":["Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study."],"pmcid":["PMC9346260"],"pubmed_authors":["Han MH","Singer B","Mao-Draayer Y","Elam C","Williams IM","Bar-Or A","Cohen JA","Meng X","FLUENT study investigators","Ziehn M","Weiss JL","Cree BA","Cox GM"],"additional_accession":[]},"is_claimable":false,"name":"Immune cell subset profiling in multiple sclerosis after fingolimod initiation and continued treatment: The FLUENT study.","description":"<h4>Background</h4>Fingolimod is a sphingosine 1-phosphate receptor modulator approved for relapsing MS. Long-term effects on the immunological profile are not fully understood.<h4>Objective</h4>Investigate fingolimod's temporal effects on immune cell subsets, and safety outcomes.<h4>Methods</h4>In FLUENT, a 12-month, prospective, non-randomized, open-label, phase IV study, adult participants received fingolimod 0.5 mg/day. Changes in immune cell subsets, anti-John Cunningham virus (JCV) antibody index, and serum neurofilament levels were assessed.<h4>Results</h4>165 fingolimod-naive and 217 participants treated for 2-12 years in routine clinical practice were enrolled. Levels of all monitored peripheral lymphocyte subsets were reduced from month 3 in fingolimod-naive participants. Greates","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul-Sep","modification":"2026-07-14T15:52:11.488Z","creation":"2024-11-09T20:30:29.52Z"},"accession":"S-EPMC9346260","cross_references":{"pubmed":["35936922"],"doi":["10.1177/20552173221115023"]}}